The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
Males or females aged 18 to 75 years;
Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma;
Patients who have not received prior systemic anti-tumor therapy for the current recurrent or metastatic disease;
At least one measurable tumor lesion according to RECIST 1.1;
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastasis;
Other malignancies within the past 5 years;
Known hypersensitivity to any monoclonal antibodies or chemotherapy components;
Gastrointestinal abnormalities;